Company Fresenius Kabi Oncology Ltd
Equities
INE575G01010
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- INR | - |
2016 | AstraZeneca sells rights to anaesthetics for up to $770 million | RE |
2015 | Fresenius SE KGaA : Kabi sells German oncology compounding business | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 30/06/18 | |
Rahul Sharma
DFI | Director of Finance/CFO | - | - |
Maria Gobbi
CHM | Chairman | - | 12/11/14 |
Director/Board Member | - | 20/07/07 | |
Director/Board Member | 63 | 10/08/08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 10/08/08 | |
Director/Board Member | - | 20/07/07 | |
Maria Gobbi
CHM | Chairman | - | 12/11/14 |
Director/Board Member | - | 09/05/19 | |
Chief Executive Officer | - | 30/06/18 | |
Maurizio Villa
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 480,427,326 | 0 | 0 | - |
Company contact information
Fresenius Kabi Oncology Ltd.
Echelon Institutional Area Plot No-11, Sector-32
122001, Gurgaon
+91 12 4488 5000
http://www.fresenius-kabi-oncology.comSector
1st Jan change | Capi. | |
---|---|---|
+19.11% | 125B | |
+13.85% | 108B | |
-4.46% | 24.57B | |
+3.35% | 22.82B | |
-11.00% | 18.19B | |
-41.48% | 16.54B | |
-12.11% | 16.5B | |
+1.62% | 13.39B | |
+21.56% | 11.1B |
- Stock Market
- Equities
- Stock
- Company Fresenius Kabi Oncology Ltd